Therapeutic Solutions
International Launches
Multi-Protocol Cancer Immunotherapy
Clinical Trial
with Pan Am Cancer Treatment
Centers
Company Aims to Leverage
Transfer Factor Pulsed Autologous Dendritic Cells on
StemVacs Platform with
Patented Augmenter of Cancer
Immunotherapy NanoStilbene
Oceanside, CA
--
May
01,
2018 -- InvestorsHub
NewsWire -- Therapeutic Solutions
International, Inc.,
(OTC
Markets:
TSOI) announced today
signing of an agreement with
the Pan
Am Cancer Treatment Center covering production and clinical
implementation of its
patent
pending StemVacs Platform in
combination
with our
Patented
immunological
adjuvant
NanoStilbene.
StemVacs is generated
using dendritic cell progenitors isolated from patients, which are
activated by a proprietary process which has previously been
demonstrated to endow dendritic cells with the ability to produce
"natural cytokines", which kill cancer cells. NanoStilbene,
a nanoparticle formulation
of
pterostilbene is covered for use in cancer immunotherapy under the
Company's issued U.S. Patent No.: 9,682,047. Pterostilbene is the
active ingredient in the Company's patented ProJuvenol
product.
StemVacs is also
subject of a filed Investigational New Drug Application (IND
#17448) with the U.S. FDA. The
IND
seeks to
establish safety and immune response of cancer, targeting a new
personalized dendritic cell vaccine.
The
Pan Am Cancer Treatment Center is a premier clinical research and
treatment facility located in Tijuana,
Mexico, which has been
offering dendritic cell therapy for treatment of cancer patients.
The current collaboration will leverage existing cellular therapy
manufacturing expertise to develop and clinically apply,
transfer
factor
pulsed
autologous
dendritic
cells on
the
StemVacs
Platform to
patients.
"Having previously
treated 10 patients with StemVacs in a proof-of-concept
trial in
collaboration with the Pan Am
Cancer
Treatment Center, we are very excited
to expand the number of
patients receiving this investigational immunotherapeutic
approach" said
Timothy
Dixon, President and Chief Executive Officer of TSOI.
"Under Compassionate
Use and Right to Try, we
are able to offer this fee-for-service treatment not available
anywhere else in the world and very pleased to do so and even more
pleased that every patient treated will also be adding NanoStilbene
to their personalized treatment protocol"
"We
are eager to offer this multi-protocol
cancer
immunotherapy to our patients, many of which who do not have
any
other
treatment
options available," said
Dr.
Javier
Lopez, Chief Executive Officer of the Pan American Cancer
Treatment Center. "By working with
internationally renowned experts, such as the Scientific Advisory
Board of Therapeutic Solutions International, we will strive to
provide the most advanced immunotherapy for our
patients."
"StemVacs is an
immuno-oncology cellular therapy that programs the immune system to
selectively attack malignant cells expressing the protein CTCFL,
which acts as a "Master Orchestrator" of numerous genes needed for
cancer to be cancer. Specifically, CTCFL is known to induce genes
associated with cancer spreading,
cancer mutating, and cancer becoming resistant to conventional
therapies" said Thomas E Ichim,
Ph.D., Board Member of
TSOI. "Recent studies have found an association
between
CTCFL and cancer stem cells, suggesting the possibility that
StemVacs actively destroys the "root" of the tumor, thus
potentially increasing the probability of efficacy. I am
particularly excited about the combination with NanoStilbene, whose
active ingredient has previously been reported to possess activity
against breast cancer and prostate cancer, the two cancers that we
are actively treating."
About Therapeutic Solutions International,
Inc.
The
Company's corporate website is www.therapeuticsolutionsint.com. Our
new products can be viewed on www.projuvenol.com and products can
be ordered at www.youcanordernow.com.
These
Supplement products have not been evaluated by the United States
Food and Drug Administration. These products are not intended to
diagnose, treat, cure or prevent any diseases.
Safe
Harbor Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT INFORMATION
Therapeutic Solutions
International, Inc.
ir@tsoimail.com
Pan Am
Cancer Treatment Center contact information:
Telephone: (619) 735-9581
Diego Rivera #2339 suite 108
Zona Rio, Tijuana B.C. 22010
www.cancerimmunotherapy.mx
info@cancerimmunotherapy.mx
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024